Global Non-Invasive Liquid Biopsy Market - GLOBAL:2021

Market Report Coverage :
Start Year : 2021 - Forecast Year : 2031 - Start Value : $1,482.5 Million in 2021 - Forecast Value : $9,470.3 Million by 2031 - CAGR % : 0.2%
Description :
Market Report Coverage - Non-Invasive Liquid BiopsyMarket Segmentation• Offering– Products (Kits and Assays) and Services• Sample – Stool, Urine, Saliva, and Other Samples• Application – Oncology, Reproductive Health, Metabolic Disorders, and Other Applications• Technology – Polymerase Chain Reaction (RT-PCR and dPCR), Sequencing (NGS and Sanger Sequencing), Microarray, and Other Technologies• End User – Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Other End UsersRegional Segmentation• North America – U.S., and Canada• Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe• Asia-Pacific – China, Japan, India, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific• Latin America – Brazil, Mexico, and Rest-of-Latin America• Rest-of-the-WorldMarket Growth Drivers• Global Increase in Cancer Prevalence• Increasing Government Funding for Healthcare• Rise in Patient Preference for Non-Invasive Cancer Diagnosis• Growing Prominence of Precision Medicine in the Oncology EcosystemMarket Challenges• False Negatives and Positives• Lack of Favorable Reimbursement Policies• Existing Diagnostic Confidence on Conventional Tissue-Based BiopsiesMarket Opportunities• Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy• Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging MarketsKey Companies ProfiledBio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Zymo Research CorporationKey Questions Answered in this Report:• How is non-invasive liquid biopsy revolutionizing the field of oncology, reproductive health, and metabolic disorders?• What are the major market drivers, challenges, and opportunities in the global non-invasive liquid biopsy market?• What are the underlying structures resulting in the emerging trends within the global non-invasive liquid biopsy market?• How did the COVID-19 pandemic impact the global non-invasive liquid biopsy ecosystem?• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?• What are the key regulatory implications in developed and developing regions pertaining to the use of non-invasive liquid biopsy?• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region? • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments: o Offering (products and services) o Sample (stool, urine, saliva, and other samples) o Technology (sequencing, polymerase chain reaction (PCR), microarray, and other technologies) o Application (oncology, reproductive health, metabolic disorders, and other applications) o End User (academic and research institutions, hospitals and diagnostic laboratories, and other end users) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the growth opportunities for the non-invasive liquid biopsy companies in the region of their operation?• Who are the leading players with significant offerings in the global non-invasive liquid biopsy market? • Which companies are anticipated to be highly disruptive in the future, and why?Market OverviewOur healthcare experts have found the non-invasive liquid biopsy industry to be one of the most rapidly evolving and dynamic markets, and the global market for non-invasive liquid biopsy is predicted to grow at a CAGR of 20.38% over the forecast period 2021-2031. The market is driven by certain factors, which include a global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.The market is favored by the developments in the field of cancer molecular diagnostic testing and its attributes such as non-invasive liquid biopsy. Currently, the non-invasive liquid biopsy industry is witnessing an upsurge due to the global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.Furthermore, biotechnology companies are focusing on the development of robust non-invasive liquid biopsy solutions for a wide range of applications, including oncology, reproductive health, metabolic disorders, to support clinicians to unravel insights pertaining to the analysis of genetic alterations present in the circulating biomarkers in samples such as stool, urine, and saliva. The development of non-invasive liquid biopsy products and services enabled clinicians to offer early cancer screening and diagnosis to patients, further improving survival rates.Within the research report, the market is segmented on the basis of offering, sample, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies to further invest in the development of innovative cancer diagnostics, including non-invasive liquid biopsy, further aiding physicians to offer value-based clinical outcomes to patients. Due to the established presence of Exact Sciences Corporation in the U.S. market, offering its proprietary Cologuard test, the company has been the leading player in the non-invasive liquid biopsy ecosystem.On the basis of region, North America holds the largest share of the non-invasive liquid biopsy market due to high infusion of funding from the government organizations for conducting cancer research, increasing prevalence of cancer, presence of market juggernauts in the region, growing awareness about non-invasive liquid biopsy products, and increasing awareness about early cancer screening. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Netherlands Rest-of-EuropeAsia-Pacific China Japan India South Korea Australia Singapore Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin-AmericaRest-of-the-World
Keywords :
Non Invasive Liquid Biopsy Market, Non Invasive Liquid Biopsy Industry, Non Invasive Liquid Biopsy Report, Non Invasive Liquid Biopsy Market Forecasts, Non Invasive Liquid Biopsy Market Trends, Non Invasive Liquid Biopsy Market Companies, Non Invasive Liquid Biopsy Market Analysis, Non Invasive Liquid Biopsy Industry Analysis, What is Non Invasive Liquid Biopsy, Non Invasive Liquid Biopsy Definition, Non Invasive Liquid Biopsy Market Competitive Landscape, Non Invasive Liquid Biopsy Market Drivers, Non Invasive Liquid Biopsy Market Segments, Non Invasive Liquid Biopsy Market Outlook, Non Invasive Liquid Biopsy Market Opportunity, Non Invasive Liquid Biopsy Market Growth, Non Invasive Liquid Biopsy Market Share, Non Invasive Liquid Biopsy Market Size, Non Invasive Liquid Biopsy Market by Offering, Non Invasive Liquid Biopsy Market by Sample, Non Invasive Liquid Biopsy Market by Application, Non Invasive Liquid Biopsy Market by Technology, Non Invasive Liquid Biopsy Market by End User, Non Invasive Liquid Biopsy Market by Region, Kits Non Invasive Liquid Biopsy Market, Assays Non Invasive Liquid Biopsy Market, Services Non Invasive Liquid Biopsy Market, Stool Non Invasive Liquid Biopsy Market, Urine Non Invasive Liquid Biopsy Market, Saliva Non Invasive Liquid Biopsy Market, Oncology Non Invasive Liquid Biopsy Market, Reproductive Health Non Invasive Liquid Biopsy Market, Metabolic Disorders Non Invasive Liquid Biopsy Market, Real-Time PCR Non Invasive Liquid Biopsy Market, Digital PCR Non Invasive Liquid Biopsy Market, Next-Generation Sequencing Non Invasive Liquid Biopsy Market, Sanger Sequencing Non Invasive Liquid Biopsy Market, Microarray Non Invasive Liquid Biopsy Market, Hospitals and Diagnostic Laboratories Non Invasive Liquid Biopsy Market, Academic and Research Institutions Non Invasive Liquid Biopsy Market, North America Non Invasive Liquid Biopsy Market, Europe Non Invasive Liquid Biopsy Market, Asia-Pacific Non Invasive Liquid Biopsy Market, Latin America Non Invasive Liquid Biopsy Market
Press Release :
The global non-invasive liquid biopsy market is projected to reach $9.47 billion by 2031, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 20.38% during the period between 2021 and 2031.The comprehensive study of the global non-invasive liquid biopsy market by BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • More than 50 products present in the market• Evaluation of over 20 brands • Market share analysis for more than 15 product categories• End-user preference data for over 20 end users• Detailed global and regional market share analysis, including the scrutiny of more than 16 countries • Study of data of more than 20 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 40+ products.BIS Research study indicates that the global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem are fueling the growth of the global non-invasive liquid biopsy market.The market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as the amalgamation of artificial intelligence (AI) with non-invasive liquid biopsy and massive scope for the adoption of non-invasive liquid biopsy tests in the emerging markets.To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include offering, sample, applications, technology, end user, and region. The offering, technology, and the region segment have been further sub-segmented to offer an in-depth analysis of the global non-invasive liquid biopsy market.The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analyses of preferred non-invasive liquid biopsy products and services. Pertaining to the market segmentation, the offering segment has been segmented into products and services. The product sub-segment under offering includes kits and assays. The sample segment of the market has been classified into stool, urine, saliva, and other samples.The technology segment has been broadly segmented into polymerase chain reaction (PCR), sequencing, microarray, and other technologies. The PCR sub-segment has been further segmented into real-time PCR and digital (PCR). Similarly, the sequencing segment has been further segmented into next-generation sequencing (NGS) and Sanger sequencing. Further, the application segment of the market has been segmented into oncology, reproductive health, metabolic disorders, and other applications. Finally, the end user segment has been segmented into hospitals and diagnostic laboratories, academic and research institutions, and other end users.Emphasizing the dominance of the North America region in the global non-invasive liquid biopsy market in 2021 and 2031, Nitish Singh, Principal Analyst – BIS Research, states, " In North America, several emerging and legacy companies are focusing on expanding their respective non-invasive liquid biopsy portfolios, majorly for oncology applications. Moreover, the significant uptake of cancer research activities, increasing fund infusions, rising awareness among patients regarding non-invasive cancer diagnostics, and growing prevalence of cancer in the region have massively promoted the adoption of non-invasive liquid biopsy products and services by the end users.”Key insights have been drawn from in-depth interviews with the key opinion leaders of more than 16 leading companies, market participants, and vendors. The key players profiled in the report include Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research Corporation.The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers and service providers involved in the development and commercialization of non-invasive liquid biopsy products and services• Emerging companies in the field of non-invasive liquid biopsy to assess the market situationHow can market intelligence on non-invasive liquid biopsy add value to an organization’s decision-making process?• Aid in product and service development • Help in targeting a segment for launching new products and services• Offer go-to-market access strategies • Support in diversifying the product and service portfolio basis risk and progression of underlying technologies• Help in analyzing specifications• Aid in understanding the end-user landscape• Gain holistic views pertaining to the regions and understand the market potential of the countries.• Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companiesInsightful Questions Covered to Enable Companies take Strategic Decisions• How is non-invasive liquid biopsy revolutionizing the field of oncology, reproductive health, and metabolic disorders?• What are the major market drivers, challenges, and opportunities in the global non-invasive liquid biopsy market?• What are the underlying structures resulting in the emerging trends within the global non-invasive liquid biopsy market?• How did the COVID-19 pandemic impact the global non-invasive liquid biopsy ecosystem?• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?• What are the key regulatory implications in developed and developing regions pertaining to the use of non-invasive liquid biopsy?• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments: o Offering (products and services) o Sample (stool, urine, saliva, and other samples) o Technology (sequencing, polymerase chain reaction (PCR), microarray, and other technologies) o Application (oncology, reproductive health, metabolic disorders, and other applications) o End User (academic and research institutions, hospitals and diagnostic laboratories, and other end users) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the growth opportunities for the non-invasive liquid biopsy companies in the region of their operation?• Who are the leading players with significant offerings in the global non-invasive liquid biopsy market?• Which companies are anticipated to be highly disruptive in the future, and why?
Companies Mentioned :
Bio-Techne CorporationEndress + Hauser GroupExact Sciences CorporationLonza Group AGMDxHealthMerck KGaAMutantDxNorgen Biotek CorpNucleix Ltd.Oasis Diagnostics CorporationOraSure Technologies, Inc.PerkinElmer Inc.Predicine, Inc.QIAGEN N.V.Thermo Fisher Scientific Inc.Zymo Research Corporation
Press Release :
The global non-invasive liquid biopsy market is projected to reach $9.47 billion by 2031, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 20.38% during the period between 2021 and 2031.The comprehensive study of the global non-invasive liquid biopsy market by BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • More than 50 products present in the market• Evaluation of over 20 brands • Market share analysis for more than 15 product categories• End-user preference data for over 20 end users• Detailed global and regional market share analysis, including the scrutiny of more than 16 countries • Study of data of more than 20 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 40+ products.BIS Research study indicates that the global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem are fueling the growth of the global non-invasive liquid biopsy market.The market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as the amalgamation of artificial intelligence (AI) with non-invasive liquid biopsy and massive scope for the adoption of non-invasive liquid biopsy tests in the emerging markets.To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include offering, sample, applications, technology, end user, and region. The offering, technology, and the region segment have been further sub-segmented to offer an in-depth analysis of the global non-invasive liquid biopsy market.The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analyses of preferred non-invasive liquid biopsy products and services. Pertaining to the market segmentation, the offering segment has been segmented into products and services. The product sub-segment under offering includes kits and assays. The sample segment of the market has been classified into stool, urine, saliva, and other samples.The technology segment has been broadly segmented into polymerase chain reaction (PCR), sequencing, microarray, and other technologies. The PCR sub-segment has been further segmented into real-time PCR and digital (PCR). Similarly, the sequencing segment has been further segmented into next-generation sequencing (NGS) and Sanger sequencing. Further, the application segment of the market has been segmented into oncology, reproductive health, metabolic disorders, and other applications. Finally, the end user segment has been segmented into hospitals and diagnostic laboratories, academic and research institutions, and other end users.Emphasizing the dominance of the North America region in the global non-invasive liquid biopsy market in 2021 and 2031, Nitish Singh, Principal Analyst – BIS Research, states, " In North America, several emerging and legacy companies are focusing on expanding their respective non-invasive liquid biopsy portfolios, majorly for oncology applications. Moreover, the significant uptake of cancer research activities, increasing fund infusions, rising awareness among patients regarding non-invasive cancer diagnostics, and growing prevalence of cancer in the region have massively promoted the adoption of non-invasive liquid biopsy products and services by the end users.”Key insights have been drawn from in-depth interviews with the key opinion leaders of more than 16 leading companies, market participants, and vendors. The key players profiled in the report include Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research Corporation.The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers and service providers involved in the development and commercialization of non-invasive liquid biopsy products and services• Emerging companies in the field of non-invasive liquid biopsy to assess the market situationHow can market intelligence on non-invasive liquid biopsy add value to an organization’s decision-making process?• Aid in product and service development • Help in targeting a segment for launching new products and services• Offer go-to-market access strategies • Support in diversifying the product and service portfolio basis risk and progression of underlying technologies• Help in analyzing specifications• Aid in understanding the end-user landscape• Gain holistic views pertaining to the regions and understand the market potential of the countries.• Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companiesInsightful Questions Covered to Enable Companies take Strategic Decisions• How is non-invasive liquid biopsy revolutionizing the field of oncology, reproductive health, and metabolic disorders?• What are the major market drivers, challenges, and opportunities in the global non-invasive liquid biopsy market?• What are the underlying structures resulting in the emerging trends within the global non-invasive liquid biopsy market?• How did the COVID-19 pandemic impact the global non-invasive liquid biopsy ecosystem?• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?• What are the key regulatory implications in developed and developing regions pertaining to the use of non-invasive liquid biopsy?• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments: o Offering (products and services) o Sample (stool, urine, saliva, and other samples) o Technology (sequencing, polymerase chain reaction (PCR), microarray, and other technologies) o Application (oncology, reproductive health, metabolic disorders, and other applications) o End User (academic and research institutions, hospitals and diagnostic laboratories, and other end users) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the growth opportunities for the non-invasive liquid biopsy companies in the region of their operation?• Who are the leading players with significant offerings in the global non-invasive liquid biopsy market?• Which companies are anticipated to be highly disruptive in the future, and why?
Headline :
Global Non-Invasive Liquid Biopsy Market to Reach $9.47 Billion by 2031
Table of Contents :
1 Product Definition1.1 Inclusion and Exclusion2 Market Scope2.1 Scope of the Study2.2 Key Questions Answered in the Report3 Research Methodology3.1 Global Non-Invasive Liquid Biopsy Market: Research Methodology3.2 Data Sources3.2.1 Primary Data Sources3.2.2 Secondary Data Sources3.3 Market Estimation Model3.4 Criteria for Company Profiling4 Market Overview4.1 Market Definition4.2 Emerging Applications of Non-Invasive Liquid Biopsy4.3 Market Footprint and Growth Potential, $Million, 2020-20314.4 COVID-19 Impact on the Global Non-Invasive Liquid Biopsy Market5 Industry Analysis5.1 Overview5.2 Legal Requirements and Framework in the U.S.5.2.1 FDA Regulation5.2.2 CMS Regulation5.3 Legal Requirements and Frameworks in Europe5.4 Legal Requirements and Frameworks in Asia-Pacific5.4.1 China5.4.2 Japan5.5 Reimbursement Analysis5.6 Return on Investment (RoI) Analysis6 Market Dynamics6.1 Overview6.2 Impact Analysis6.3 Market Drivers6.3.1 Global Increase in Cancer Prevalence6.3.2 Increasing Government Funding for Healthcare6.3.3 Rise in Patient Preference for Non-Invasive Cancer Diagnosis6.3.4 Growing Prominence of Precision Medicine in the Oncology Ecosystem6.4 Market Restraints6.4.1 False Negatives and Positives6.4.2 Lack of Favorable Reimbursement Policies6.4.3 Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies6.5 Market Opportunities6.5.1 Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy6.5.2 Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets7 Competitive Landscape7.1 Synergistic Activities7.2 Product Approvals7.3 Product Launches7.4 Acquisitions7.5 Funding and Other Activities7.6 Market Share Analysis, 2019-20207.7 Growth-Share Analysis7.7.1 Growth-Share Analysis (by Company)7.7.2 Growth-Share Analysis (by Technology)7.7.3 Growth-Share Analysis (by Application)7.8 Pricing Analysis7.8.1 Price with Sample Type8 Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-20318.1 Overview8.2 Offering8.2.1 Kits8.2.2 Assays8.3 Services9 Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2021-20319.1 Overview9.2 Stool9.3 Urine9.4 Saliva9.5 Other Samples10 Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-203110.1 Overview10.2 Oncology10.3 Reproductive Health10.4 Metabolic Disorders10.5 Other Applications11 Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020-203111.1 Overview11.2 Polymerase Chain Reaction (PCR)11.2.1 Real-Time PCR (RT-PCR)11.2.2 Digital PCR (dPCR)11.3 Sequencing11.3.1 Next-Generation Sequencing (NGS)11.3.2 Sanger Sequencing11.4 Microarray11.5 Other Technologies12 Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-203112.1 Overview12.2 Hospitals and Diagnostic Laboratories12.3 Academic and Research Institutions12.4 Other End Users13 Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-203113.1 Overview13.2 North America13.2.1 U.S.13.2.2 Canada13.2.3 North America Non-Invasive Liquid Biopsy Market (by Application)13.3 Europe13.3.1 Germany13.3.2 U.K.13.3.3 France13.3.4 Italy13.3.5 Spain13.3.6 Netherlands13.3.7 Rest-of-Europe13.3.8 Europe Non-Invasive Liquid Biopsy Market (by Application)13.4 Asia-Pacific (APAC)13.4.1 China13.4.2 Japan13.4.3 India13.4.4 South Korea13.4.5 Australia13.4.6 Singapore13.4.7 Rest-of-Asia-Pacific (RoAPAC)13.4.8 Asia-Pacific Non-Invasive Liquid Biopsy Market (by Application)13.5 Latin America (LATAM)13.5.1 Brazil13.5.2 Mexico13.5.3 Rest-of-Latin America (RoLA)13.5.4 Latin America Non-Invasive Liquid Biopsy Market (by Application)13.6 Rest-of-the-World13.6.1 Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application)14 Company Profiles14.1 Overview14.2 Bio-Techne Corporation14.2.1 Company Overview14.2.2 Role of Bio-Techne Corporation in the Global Non-Invasive Liquid Biopsy Market14.2.3 Financials14.2.4 Key Insights About Financial Health of the Company14.2.5 SWOT Analysis14.3 Endress + Hauser Group14.3.1 Company Overview14.3.2 Role of Endress + Hauser Group in the Global Non-Invasive Liquid Biopsy Market14.3.3 Financials14.3.4 Key Insights About Financial Health of the Company14.3.5 SWOT Analysis14.4 Exact Sciences Corporation14.4.1 Company Overview14.4.2 Role of Exact Sciences Corporation in the Global Non-invasive Liquid Biopsy Market14.4.3 Financials14.4.4 Key Insights About Financial Health of the Company14.4.5 SWOT Analysis14.5 Lonza Group AG14.5.1 Company Overview14.5.2 Role of Lonza Group AG in the Global Non-Invasive Liquid Biopsy Market14.5.3 Financials14.5.4 Key Insights About Financial Health of the Company14.5.5 SWOT Analysis14.6 MDxHealth14.6.1 Company Overview14.6.2 Role of MDxHealth in the Global Non-Invasive Liquid Biopsy Market14.6.3 Financials14.6.4 Key Insights About Financial Health of the Company14.6.5 SWOT Analysis14.7 Merck KGaA14.7.1 Company Overview14.7.2 Role of Merck KGaA in the Global Non-Invasive Liquid Biopsy Market14.7.3 Financials14.7.4 Key Insights About Financial Health of the Company14.7.5 SWOT Analysis14.8 MutantDx14.8.1 Company Overview14.8.2 Role of MutantDx in the Global Non-Invasive Liquid Biopsy Market14.8.3 SWOT Analysis14.9 Norgen Biotek Corp14.9.1 Company Overview14.9.2 Role of Norgen Biotek Corp in the Global Non-Invasive Liquid Biopsy Market14.9.3 SWOT Analysis14.1 Nucleix Ltd.14.10.1 Company Overview14.10.2 Role of Nucleix Ltd. in the Global Non-Invasive Liquid Biopsy Market14.10.3 SWOT Analysis14.11 Oasis Diagnostics Corporation14.11.1 Company Overview14.11.2 Role of Oasis Diagnostics Corporation in the Global Non-Invasive Liquid Biopsy Market14.11.3 SWOT Analysis14.12 OraSure Technologies, Inc.14.12.1 Company Overview14.12.2 Role of OraSure Technologies, Inc. in the Global Non-Invasive Liquid Biopsy Market14.12.3 Financials14.12.4 Key Insights About Financial of the Company14.12.5 SWOT Analysis14.13 PerkinElmer Inc.14.13.1 Company Overview14.13.2 Role of PerkinElmer Inc. in the Global Non-Invasive Liquid Biopsy Market14.13.3 Financials14.13.4 Key Insights About Financial Health of the Company14.13.5 SWOT Analysis14.14 Predicine, Inc.14.14.1 Company Overview14.14.2 Role of Predicine, Inc. in the Global Non-Invasive Liquid Biopsy Market14.14.3 SWOT Analysis14.15 QIAGEN N.V.14.15.1 Company Overview14.15.2 Role of QIAGEN N.V. in the Global Non-Invasive Liquid Biopsy Market14.15.3 Financials14.15.4 Key Insights About Financial Health of the Company14.15.5 SWOT Analysis14.16 Thermo Fisher Scientific Inc.14.16.1 Company Overview14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Non-Invasive Liquid Biopsy Market14.16.3 Financials14.16.4 Key Insights About Financial Health of the Company14.16.5 SWOT Analysis14.17 Zymo Research Corporation14.17.1 Company Overview14.17.2 Role of Zymo Research Corporation in the Global Non-Invasive Liquid Biopsy Market14.17.3 SWOT AnalysisList of Tables Table 5.1: Classification Rules of IVDs under the IVDRTable 5.2: Key Coverage Providers for Non-Invasive Liquid Biopsy TestsTable 6.1: Likert ScaleTable 6.2: Impact Analysis of Market DriversTable 6.3: Impact Analysis of Market RestraintsList of Figures Figure 1: U.S. National Cancer Institute (NCI), Fiscal Budget Year-on-Year, 2013-2018Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Non-Invasive Liquid Biopsy MarketFigure 3: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020 and 2031Figure 4: Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2020 and 2031Figure 5: Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020 and 2031Figure 6: Global Non-Invasive Liquid Biopsy Market (by Technology), $Million, 2020 and 2031Figure 7: Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020 and 2031Figure 8: Global Non-invasive Liquid Biopsy Market SnapshotFigure 2.1: Global Non-Invasive Liquid Biopsy Market SegmentationFigure 3.1: Global Non-Invasive Liquid Biopsy Market: Research MethodologyFigure 3.2: Primary Research MethodologyFigure 3.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.4: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: Global Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 4.2: Global Non-Invasive Liquid Biopsy Market: COVID-19 Impact AnalysisFigure 5.1: Components Considered for Clinical Evidence as per the IVDRFigure 5.2: Global Non-Invasive Liquid Biopsy Market (Return on Investment (RoI) Analysis)Figure 6.1: Global Cancer Burden (by Region), 2018Figure 6.2: Increasing Government Spending for Healthcare, 2017Figure 7.1: Share of Key Developments and Strategies, January 2017–July 2021Figure 7.2: Share of Synergistic Activities (by Company), January 2017-June 2021Figure 7.3: Share of Product Approvals (by Company), January 2017-July 2021Figure 7.4: Number of Product Launches (by Company), January 2017–July 2021Figure 7.5: Share of Acquisitions (by Company), January 2017-July 2021Figure 7.6: Market Share Analysis for Global Non-Invasive Liquid Biopsy Market, $Million, 2019 and 2020Figure 7.7: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Company), 2020Figure 7.8: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Technology), 2020-2031Figure 7.9: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Application), 2020-2031Figure 8.1: Global Non-Invasive Liquid Biopsy Market (by Offering)Figure 8.2: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020 and 2031Figure 8.3: Global Non-Invasive Liquid Biopsy Market (by Offering), $Million, 2020-2031Figure 8.4: Global Non-Invasive Liquid Biopsy Market (by Offering), 2020 and 2031Figure 8.5: Global Non-Invasive Liquid Biopsy Market (Kits), $Million, 2020-2031Figure 8.6: Global Non-Invasive Liquid Biopsy Market (Assays), $Million, 2020-2031Figure 8.7: Global Non-Invasive Liquid Biopsy Market (Services), $Million, 2020-2031Figure 9.1: Global Non-Invasive Liquid Biopsy Market (by Sample), $Million, 2020-2031Figure 9.2: Global Non-Invasive Liquid Biopsy Market (by Sample), 2020 and 2031Figure 9.3: Global Non-Invasive Liquid Biopsy Market (Stool), $Million, 2020-2031Figure 9.4: Global Non-Invasive Liquid Biopsy Market (Urine), $Million, 2020-2031Figure 9.5: Global Non-Invasive Liquid Biopsy Market (Saliva), $Million, 2020-2031Figure 9.6: Global Non-Invasive Liquid Biopsy Market (Other Samples), $Million, 2020-2031Figure 10.1: Global Non-Invasive Liquid Biopsy Market (by Application)Figure 10.2: Global Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031Figure 10.3: Global Non-Invasive Liquid Biopsy Market (Oncology), $Million, 2020-2031Figure 10.4: Global Non-Invasive Liquid Biopsy Market (Reproductive Health), $Million, 2020-2031Figure 10.5: Global Non-Invasive Liquid Biopsy Market (Metabolic Disorders), $Million, 2020-2031Figure 10.6: Global Non-Invasive Liquid Biopsy Market (Other Applications), $Million, 2020-2031Figure 11.1: Global Non-Invasive Liquid Biopsy Market (by Technology)Figure 11.2: Global Non-Invasive Liquid Biopsy Market (by Technology), 2020 and 2031Figure 11.3: Global Non-Invasive Liquid Biopsy Market (PCR), $Million, 2020-2031Figure 11.4: Global Non-Invasive Liquid Biopsy Market (PCR), 2020 and 2031Figure 11.5: Global Non-Invasive Liquid Biopsy Market (RT-PCR, by PCR), $Million, 2020-2031Figure 11.6: Global Non-Invasive Liquid Biopsy Market (dPCR, by PCR), $Million, 2020-2031Figure 11.7: Global Non-Invasive Liquid Biopsy Market (Sequencing), $Million, 2020-2031Figure 11.8: Global Non-Invasive Liquid Biopsy Market (Sequencing), 2020 and 2031Figure 11.9: Global Non-Invasive Liquid Biopsy Market (NGS, by Sequencing), $Million, 2020-2031Figure 11.10: Global Non-Invasive Liquid Biopsy Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031Figure 11.11: Global Non-Invasive Liquid Biopsy Market (Microarray), $Million, 2020-2031Figure 11.12: Global Non-Invasive Liquid Biopsy Market (Other Technologies), $Million, 2020-2031Figure 12.1: Global Non-Invasive Liquid Biopsy Market (by End User)Figure 12.2: Global Non-Invasive Liquid Biopsy Market (by End User), $Million, 2020-2031Figure 12.3: Global Non-Invasive Liquid Biopsy Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2031Figure 12.4: Global Non-Invasive Liquid Biopsy Market (Academic and Research Institutions), $Million, 2020-2031Figure 12.5: Global Non-Invasive Liquid Biopsy Market (Other End Users), $Million, 2020-2031Figure 13.1: Global Non-Invasive Liquid Biopsy Market (by Region): Market SnapshotFigure 13.2: Global Non-Invasive Liquid Biopsy Market (by Region), $Million, 2020-2031Figure 13.3: North America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.4: North America: Market DynamicsFigure 13.5: North America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031Figure 13.6: U.S. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.7: Canada Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.8: North America Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031Figure 13.9: Europe Non-invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.10: Europe: Market DynamicsFigure 13.11: Europe Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031Figure 13.12: Germany Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.13: U.K. Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.14: France Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.15: Italy Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.16: Spain Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.17: Netherlands Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.18: Rest-of-Europe Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.19: Europe Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031Figure 13.20: Asia-Pacific Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.21: APAC Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031Figure 13.22: China Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.23: Japan Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.24: India Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.25: South Korea Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.26: Australia Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.27: Singapore Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.28: RoAPAC Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.29: APAC Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031Figure 13.30: Latin America Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.31: Latin America: Market DynamicsFigure 13.32: Latin America Non-Invasive Liquid Biopsy Market (by Country), $Million, 2020-2031Figure 13.33: Brazil Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.34: Mexico Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.35: RoLA Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.36: LATAM Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031Figure 13.37: Rest-of-the-World Non-Invasive Liquid Biopsy Market, $Million, 2020-2031Figure 13.38: Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application), $Million, 2020-2031Figure 14.1: Total Number of Companies ProfiledFigure 14.2: Bio-Techne Corporation: Service PortfolioFigure 14.3: Bio-Techne Corporation: Overall Financials, 2018-2020Figure 14.4: Bio-Techne Corporation: Revenue (by Segment), 2018-2020Figure 14.5: Bio-Techne Corporation: Revenue (by Region), 2018-2020Figure 14.6: Bio-Techne Corporation: R&D Expenditure, 2018-2020Figure 14.7: Bio-Techne Corporation: SWOT AnalysisFigure 14.8: Endress + Hauser Group: Product PortfolioFigure 14.9: Endress + Hauser Group: Overall Financials, 2018-2020Figure 14.10: Endress + Hauser Group: Revenue (by Segment), 2018-2020Figure 14.11: Endress + Hauser Group: Revenue (by Region), 2018-2020Figure 14.12: Endress + Hauser Group: R&D Expenditure, 2018-2020Figure 14.13: Endress + Hauser Group: SWOT AnalysisFigure 14.14: Exact Sciences Corporation: Service PortfolioFigure 14.15: Exact Sciences Corporation: Overall Financials, 2018-2020Figure 14.16: Exact Sciences Corporation: Revenue (by Segment), 2018-2020Figure14.17: Exact Sciences Corporation: Revenue (by Region), 2018-2020Figure 14.18: Exact Sciences Corporation: R&D Expenditure, 2018-2020Figure 14.19: Exact Sciences Corporation: SWOT AnalysisFigure 14.20: Lonza Group AG: Product PortfolioFigure 14.21: Lonza Group AG: Overall Financials, 2018-2020Figure 14.22: Lonza Group AG: Revenue (by Segment), 2018-2020Figure 14.23: Lonza Group AG: Revenue (by Region), 2018-2020Figure 14.24: Lonza Group AG: R&D Expenditure, 2018-2020Figure 14.25: Lonza Group AG: SWOT AnalysisFigure 14.26: MDxHealth: Service PortfolioFigure 14.27: MDxHealth: Overall Financials, 2018-2020Figure 14.28: MDxHealth: Revenue (by Segment), 2018-2020Figure 14.29: MDxHealth: Revenue (by Region), 2018-2020Figure 14.30: MDxHealth: R&D Expenditure, 2018-2020Figure 14.31: MDxHealth: SWOT AnalysisFigure 14.32: Merck KGaA: Product PortfolioFigure 14.33: Merck KGaA: Overall Financials, 2018-2020Figure 14.34: Merck KGaA: Revenue (by Segment), 2018-2020Figure 14.35: Merck KGaA: Revenue (by Region), 2018-2020Figure 14.36: Merck KgaA: R&D Expenditure, 2018-2020Figure 14.37: Merck KGaA: SWOT AnalysisFigure 14.38: MutantDx: Product PortfolioFigure 14.39: MutantDx: SWOT AnalysisFigure 14.40: Norgen Biotek Corp: Product PortfolioFigure 14.41: Norgen Biotek Corp: SWOT AnalysisFigure 14.42: Nucleix Ltd.: Product PortfolioFigure 14.43: Nucleix Ltd.: SWOT AnalysisFigure 14.44: Oasis Diagnostics Corporation: Product PortfolioFigure 14.45: Oasis Diagnostics Corporation: SWOT AnalysisFigure 14.46: OraSure Technologies, Inc.: Product PortfolioFigure 14.47: OraSure Technologies, Inc.: Overall Financials, 2018-2020Figure 14.48: OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020Figure 14.49: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), 2019-2020Figure 14.50: OraSure Technologies, Inc.: Revenue (by Region), 2018-2020Figure 14.51: OraSure Technologies, Inc.: R&D Expenditure, 2018-2020Figure 14.52: OraSure Technologies, Inc.: SWOT AnalysisFigure 14.53: PerkinElmer Inc.: Product PortfolioFigure 14.54: PerkinElmer Inc.: Overall Financials, 2018-2020Figure 14.55: PerkinElmer Inc.: Revenue (by Segment), 2018-2020Figure 14.56: PerkinElmer Inc.: Revenue (by Region), 2018-2020Figure 14.57: PerkinElmer Inc.: R&D Expenditure, 2018-2020Figure 14.58: PerkinElmer Inc.: SWOT AnalysisFigure 14.59: Predicine, Inc.: Service PortfolioFigure 14.60: Predicine, Inc.: SWOT AnalysisFigure 14.61: QIAGEN N.V.: Product PortfolioFigure 14.62: QIAGEN N.V.: Overall Financials, 2018-2020Figure 14.63: QIAGEN N.V.: Revenue (by Segment), 2018-2020Figure 14.64: QIAGEN N.V.: Revenue (by Region), 2018-2020Figure 14.65: QIAGEN N.V.: R&D Expenditure, 2018-2020Figure 14.66: QIAGEN N.V.: SWOT AnalysisFigure 14.67: Thermo Fisher Scientific Inc.: Product PortfolioFigure 14.68: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020Figure 14.69: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020Figure 14.70: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020Figure 14.71: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020Figure 14.72: Thermo Fisher Scientific Inc.: SWOT AnalysisFigure 14.73: Zymo Research Corporation: Product PortfolioFigure 14.74: Zymo Research Corporation: SWOT Analysis